Childhood cancer survivors are more than twice as likely to develop melanoma as the general population, according to findings published in Journal of Clinical Oncology.
2025
World-first experimental cancer treatment paves way for clinical trial
A peer-reviewed paper detailing the experimental cancer treatment developed by Professor Georgina Long AO, University of Sydney medical oncologist and Medical Director of the Melanoma Institute Australia, has today been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.
Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management
Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases.